Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer (NYSE:PFE) received FDA approval for VEPPANU (vepdegestrant), the first PROteolysis TArgeting Chimera, or PROTAC, therapy for certain patients with endocrine-resistant advanced breast cancer. Positive Phase 3 data for ELREXFIO in relapsed or refractory multiple myeloma were reported, supporting potential expanded use in this blood cancer setting. Settlements with generic manufacturers extended U.S. patent protection for VYNDAMAX to 2031, affecting a key cardiology franchise. For...
Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.
Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to invest in according to hedge funds. On May 5, Pfizer reported a strong start to 2026, achieving Q1 revenues of $14.5 billion, which represents a 2% operational increase compared to the prior-year period. This growth was driven by a 22% operational revenue surge […]
If you are trying to generate income in retirement, these three high-yield healthcare stocks could be the perfect fit for you.
BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.
Is Pfizer a yield trap? No way.
In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings per share easing slightly year on year while the company reaffirmed full-year 2026 revenue guidance of US$59.5 billion to US$62.5 billion and filed an US$8.42 billion employee share offering shelf registration. At the same time, Pfizer advanced its oncology franchise with positive Phase 3 data for multiple myeloma drug ELREXFIO and secured the first-ever FDA approval...
Investors often move like lemmings in the short term, giving long-term investors an opportunity to buy great companies.
Pfizer’s first-quarter results gave investors a clearer view of how much work the drugmaker’s newer portfolio is doing as the company continues moving away from its pandemic-era sales base. In a report given to TheStreet, Pfizer said revenue rose from a year earlier, helped by recently launched and ...
Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par
Pfizer (NYSE:PFE) chief executive Albert Bourla has signaled a possible shift in tone around US vaccine policy, praising President Donald Trump's latest nominee to lead the Centers for Disease Control and Prevention after a turbulent year for the agency. In a Bloomberg TV interview Tuesday, Bourla called Erica Schwartz a very credible scientist, pointing to what could be a more conventional choice for the country's top public health role. Schwartz, who holds both medical and law degrees and previously served as deputy surgeon general during the first Trump administration, is now being viewed as a figure who could help stabilize an agency that has become increasingly important for vaccine makers.
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
Pfizer (PFE) is back in focus after reporting first quarter 2026 results that topped analyst expectations, reaffirmed its full year guidance, and paired those figures with fresh product, legal and regulatory updates. See our latest analysis for Pfizer. Despite the earnings beat and a series of product, legal and regulatory updates in oncology and rare disease, market reaction has been measured, with a year to date share price return of 5.04% and 1 year total shareholder return of 23.99%. This...
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, respectively.
FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast cancer. Pfizer and Arvinas co developed VEPPANU, targeting patients who face significant challenges with endocrine resistance. Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma report positive outcomes, strengthening Pfizer's oncology pipeline. For investors following NYSE:PFE, these oncology milestones arrive with the stock trading around $26.3...
Moby summary of Pfizer Inc.'s Q1 2026 earnings call
Pfizer Chief Executive Albert Bourla is battling impending expirations for some blockbuster-drug patents and the precipitous decline of the company's Covid franchise, but he has put a date on when the company will return to consistent growth: 2029. Bourla said Tuesday he expects Pfizer will post high-single-digit average revenue growth annually from 2029 through 2033. “Products are losing patents, and we have a clear line of sight on growth starting in '29,” Bourla said in an interview after the company reported better-than-expected first-quarter results.
Pfizer topped first-quarter expectations, reaffirmed 2026 guidance, and faces pressure to prove future growth beyond Covid products.
May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine. The New York-based drugmaker also beat Wall Street expectations for first-quarter revenue and profit, buoyed by strong demand for its blood thinner Eliquis and recently acquired products, as it faces looming patent expirations and fading COVID produ
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted...
Raising capital while still building the data needed to validate an idea is often one of the biggest hurdles for start-ups.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.